The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)

Title:The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)

Volume: 15 Issue: 1

Author(s): Nisha Nathan and Shannon D. Sullivan

Affiliation:

Keywords: Gestational diabetes mellitus, hirsutism, infertility, insulin resistance, metabolic syndrome, metformin, polycystic ovary syndrome, pregnancy.

Abstract: Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women. With very little risk associated with its use, metformin provides many important benefits to women with PCOS, including regulating menstrual cycles, improving clinical signs of hyperandrogenism, ameliorating metabolic syndrome, inducing ovulation, improving pregnancy rates and pregnancy outcomes, preventing gestational diabetes, and preventing progression to T2DM. Here, we review the indications for metformin in women with PCOS, with a focus on the use of metformin during pre-conception and pregnancy.

Cite this article as:

Nathan Nisha and Sullivan D. Shannon, The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS), Current Pharmaceutical Biotechnology 2014; 15 (1) . https://dx.doi.org/10.2174/1389201015666140330195142